HOT NEWS
Novo Nordisk
Novo NordiskNovo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

Novo Nordisk RSS Channel

Title Filter     Display # 
# Article Title Hits
1 43 research talents awarded scholarships to help secure Denmark's future 631
2 Positive opinion on the use of Levemir® in children with type 1 diabetes aged two to five years 3519
3 Greater overall patient satisfaction when switching from sitagliptin to Victoza® 3599
4 Novo Nordisk to build new corporate centre in Bagsværd, Denmark 3431
5 Novo Nordisk gains EU approval for FlexTouch® 5303
6 Novo Nordisk invests 1 billion Danish kroner in new factory in Denmark 4852
7 New clinical trial data support the use of Levemir® in children aged two to five years 6297
8 Novo Nordisk increased operating profit by 27% in 2010 6394
9 44 research talents get Novo scholarships to write their master theses 6112
10 Novo Nordisk's New Pen for Children - NovoPen Echo(R) - Wins GOOD DESIGN(TM) Award 7701
11 Novo Nordisk's NovoTwist(R) Wins GOOD DESIGN(TM) Award 7113
12 Novo Nordisk A/S and Emisphere Technologies, Inc. Announce Licence Agreement 5320
13 Novo Nordisk partners with international scientific community for Victoza® cardiovascular outcomes trial 7125
14 The Lancet publishes new data demonstrating the superior efficacy of Victoza® (liraglutide) compared to Januvia® (sitagliptin) 6215
15 Danish companies join forces to compete for global talent 5622
16 Novo Nordisk starts phase 1 trial with long-acting oral GLP-1 analogue 6238
17 Novo Nordisk and Combine in research collaboration for the treatment of autoimmune diseases 4049
18 EFSD/Novo Nordisk partnership for diabetes research in Europe 4126
19 Novo Nordisk increased operating profit by 30% in the first nine months of 2009 3249
20 The Lancet publishes direct comparison study between liraglutide and exenatide 4292
 
  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  Next 
  •  End 
  • »
Page 1 of 2
Bookmark and Share